Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2005-09-09
2011-11-29
Yu, Misook (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C536S023100, C435S069100
Reexamination Certificate
active
08067529
ABSTRACT:
The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular renal cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 338 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
REFERENCES:
patent: 5912167 (1999-06-01), Palmenberg et al.
patent: 2003/0194704 (2003-10-01), Penn et al.
patent: WO03042357 (2003-05-01), None
patent: 2006/113671 (2006-10-01), None
Ng et al., 2001, Journal of Biol. Chem. vol. 201, pp. 44444-44449).
Sherman, La et al, 1998, Critical reviews in Immunol, 18(1-2): 47-54.
Lauritzsen et al (International Journal of Cancer, 1998, vol. 78, pp. 216-222.
Sarma et al (Journal of Experimental Medicine, 1999, vol. 189, pp. 811-820.
Harig et al , Blood, 98 (10): 2999-3005, 2001.
Nolling et al , J Bacteriol, 183:4824838, 2001.
Dengjel et al., “Identificatin of a naturally . . . spectrometry,” Eur. J. Immunol., 2004, pp. 3644-3651, vol. 34, No. 12, XP001206092, Germany.
Malcherek et al., “MHC class II-associated . . . presentation,” Eur. J. Immunol., May 1998, pp. 1524-1533, vol. 28, No. 5, XP001206094, GB.
Rammensee et al. “Syfpeithi: database for MHC . . . motifs,” Immunogenetics, 1999, pp. 213-219, vol. 50, No. 3-4, XP-002183663, DE.
Hedberg et al., “Expression of cyclin . . . tissue microarray,” British Journal of Cancer., 2003, pp. 1417-1423, vol. 88, No. 9, XP001206106, GB.
Chaux et al., “Identification of MAGE-3 . . . Lymphocytes,” Jr. Exp. Med., 1999, pp. 767-777, vol. 189, No. 5, XP000857617, Japan.
Ten Bosch et al., “Recognition of BCR-ABL . . . Peptide,” Blood, 1996, pp. 3522-2527, vol. 88, No. 9, XP000647337, US.
Fu et al., “Minireview: Cyclin D1:Normal..Functions,” Endocrinology, 2004, pp. 5439-5447, vol. 145, No. 12, XP009046546, US.
Borczuk et al., “Molecular Signatures in Biopsy Specimens of Lung Cancer,” AJRCCM Articles in Press; Apr. 15, 2004; The American Thoracic Society.
Maeda et al., “Suppressor T cells regulate the nonanergic cell population that remains after peripheral tolerance is induced to the Mls-1 antigen in T cell receptor vβ8.1 transgenic mice,” PNAS; Nov. 21, 2000, pp. 13257-13262; vol. 97; No. 24.
Polymenidou et al., “Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection;” PNAS; Oct. 5, 2004; pp. 14670-14676; vol. 101, suppl. 2.
Kurts et al., “CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose,” PNAS; Oct. 26, 1999; pp. 12703-12707; vol. 96, No. 22.
Sadovnikova et al., “Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: Reagents for tumor immunotherapy,” Proc. Natl. Acad. Sci.; Nov. 1996; pp. 13114-13118; vol. 93; Immunology.
Vella et al., “B cells are not essential for peripheral T-cell tolerance,” Proc. Natl. Acad. Sci.; Jan. 1996; pp. 951-955; vol. 93; Immunology.
Vidard et al., “Specific T-cell tolerance may be preceded by a primary response,” Proc. Natl. Acad. Sci.; Jun. 1994; pp. 5627-5631; vol. 91; Immunology.
Adam Adler, “Peripheral Tolerization of Effector and Memory T Cells: Implications for Autoimmunity and Tumor-Immunity,” Curr Immunol Rev.; Jan. 1, 2005; pp. 21-28; 1(1); Bentham Science Publishers Ltd.
Oehlen et al., “Expression of a Tolerizing Tumor Antigen in Peripheral Tissue Does Not Preclude Recovery of High-Affinity CD8+ T Cells or CTL Immunotherapy of Tumors Expressing the Antigen,” J. Immunol.; 2001; pp. 2863-2870; 166; The American Association of Immunologists, Inc., Bethesda, MD.
Mihalyo et al., “In Vivo Cyclophosphamide and IL-2 Treatment Impedes Self-Antigen-Induced Effector CD4 Cell Tolerization: Implications for Adoptive Immunotherapy,” J. Immunol.; 2004; pp. 5338-5345; 172; The American Association of Immunologists, Inc., Bethesda, MD.
Basil et al., “Common Cancer Biomarkers,” Cancer Res. Mar. 15, 2006; pp. 2953-2961; 66(6).
Hugh McDevitt, “Specific antigen vaccination to treat autoimmune disease,” PNAS; Oct. 5, 2004; pp. 14627-14630; vol. 101, suppl. 2; The National Academy of Sciences of the USA.
“Search of: Immunotherapy Vaccine,” ClinicalTrials.gov; Aug. 9, 2010; (http://clinicaltrials.gov/ct2/results? term=Immunotherapy+Vaccine).
Dengjel Jörn
Rammensee Hans-Georg
Weinschenk Toni
Baker Donelson Bearman Caldwell & Berkowitz PC
Immatics Biotechnologies GmbH
Yao Lei
Yu Misook
LandOfFree
Immunogenic T-helper epitopes from human tumour antigens and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogenic T-helper epitopes from human tumour antigens and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic T-helper epitopes from human tumour antigens and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4298529